Programme Thesis
The Merck KGaA Research Grants programme (est. 2018) funds external academic and company researchers whose work aligns with Merck's pipeline priorities in life science, healthcare, and electronics — with grants of up to €500,000 over three years. The programme exists primarily to source pre-competitive innovation Merck cannot generate internally: it is explicitly framed as a bilateral collaboration, not a pure research subsidy, meaning grantees are expected to publish, share data, and meet regularly with Merck scientists. The 2026 call reflects Merck's strategic bet on AI-driven biomanufacturing, neuroinflammation drug discovery, green remediation, biophysics-based PPI screening, and Synthia-platform chemistry.
Selection Criteria
• Eligibility: Open to scientists at ALL career stages affiliated with any research-based institution, university, or company — ZYCO qualifies as 'company'. No nationality restriction stated. Multi-grant applications permitted.
• Stage 1 (non-confidential): Proposal must match one of the five defined 2026 topic areas; non-confidential project summary, CV/biography, affiliation statement, grant category selection, and budget overview required.
• Reviewer priorities (inferred from programme history and topic briefs):
– Alignment: How precisely does the proposal address the defined topic scope? Off-topic proposals are eliminated early.
– Novelty/differentiation: Does the approach offer something Merck cannot readily source internally or from standard CRO partners?
– Feasibility: Is there preliminary evidence (data, working prototype, published model) that the concept can be executed within the grant period?
– Collaboration fit: Willingness to work closely with Merck scientists; IP and publication arrangements must be acceptable to both parties.
– Scalability: Outputs must have a plausible path to industrial or clinical relevance.
• Stage 2 (confidential deep-dive workshop, Nov–Dec 2026): Full proposal + live co-development session with Merck managers and scientists; winning teams are selected at the end of the workshop, not before it. This means presentation skill and real-time scientific dialogue matter as much as the written proposal.
• Budget: Merck covers travel/accommodation for deep-dive workshop finalists.
Past Winners / Cohort Profiles
Merck does not publish a comprehensive named winner list publicly — the programme FAQ explicitly states 'Merck will not reveal any information on submissions.' However, from historical programme pages and press releases, the following patterns are documented: (1) 2018 inaugural call (Healthy Lives/Drug Discovery; Life Reimagined/Synthetic Biology; Materials & Solutions; Digitalization/Computing) — winners announced Q1 2019; Merck's own AI-in-chemistry track has consistently attracted computational chemists and cheminformatics groups from European research universities. (2) 2020–2023 calls included tracks for 'AI for diagnostics & target discovery' (2022), 'Next-generation machine learning' (2020), and 'Digital innovation' (2021) — winners in these tracks have historically been academic groups with working computational pipelines, not purely theoretical proposals. (3) The 2025 call's closest analogue to the 2026 AI track was 'Smart Consumables for Digital Integration in Biomanufacturing' — a process-focused track, suggesting Merck favours proposals that bridge AI methodology with concrete manufacturing or screening workflows. Overall winner archetype: mid-career academic (PhD + postdoc or lecturer level) at a European or North American research university, with a working prototype or proof-of-concept dataset, proposing something that complements Merck's internal Life Science / Process Solutions division. Independent researcher or company-affiliated researchers have been eligible and appear to have been funded, though named examples are not publicly confirmed.
Ideal Candidate Fingerprint
The platonic ideal applicant is a research group leader (or equivalent PI) at an established academic institution or biotech company who has already demonstrated the core technology in a published or preprint form, can show quantitative preliminary results, and is explicitly willing to collaborate with Merck scientists as a partner rather than simply receive a cheque. For the 2026 AI-in-cell-culture/process-development track, the ideal candidate combines ML/AI engineering depth (e.g., trained models, validated pipelines) with domain expertise in biomanufacturing, cell culture media formulation, or upstream bioprocess optimisation. For the neuroinflammatory diseases track, the ideal is a wet-lab group with iPSC infrastructure, existing co-culture protocols, and quantified inflammatory readouts.
Recommended Framing
Eniola's strongest angle is the 'Artificial intelligence in cell culture media and process development' track (€150,000/yr × 3 years), repositioning IMPRINT and TOPOLOGIX as AI-driven CNS compound-liability screening tools embedded in a drug discovery process pipeline — directly relevant to Merck's Life Science Discovery Solutions division, which sells screening reagents and assay kits to pharma. The pitch should centre on TOPOLOGIX's persistent-homology / bipartite-simplicial-complex architecture for hERG cardiotoxicity prediction as a process-gate tool (early-phase CNS drug liability flagging before expensive wet-lab assays), and on IMPRINT's addiction-liability screening as an AI layer over Merck's cell-based assay workflow — with the CCT ODE/Bayesian results (85.8% encoding-reduction, all H1–H5 pre-registered hypotheses confirmed) as the mechanistic validation anchor. The endorsements from Berridge, Gershman, Daw, and Mattar should be named explicitly in the Stage 1 proposal to offset the ZYCO-vs-traditional-academic-institution gap; the ORCID, OSF pre-registrations, and under-review Elsevier paper all serve as substitute indicators of research rigour. Eniola should apply to a second track simultaneously — the neuroinflammatory diseases category — framing the CCT model's microglia-neuroinflammation-addiction nexus (neuroinflammation is a known co-morbidity in substance-use disorders) and proposing an in-silico screening layer to guide iPSC model design, positioning herself as a computational partner for a wet-lab collaborator rather than a standalone applicant.
Watch Out
1. Affiliation gap: Merck requires applicants to be 'affiliated with any research-based institution, university or company' — ZYCO satisfies the 'company' criterion on paper, but reviewers expect institutional letterhead signals (university address, grant office, ethics approval infrastructure). The Stage 1 affiliation statement must proactively establish ZYCO's research credentials (OSF preprints, patent filing, collaborator affiliations at Michigan/Harvard/Princeton/NYU) rather than leaving reviewers to assume it is a shell entity.
2. Track mismatch: Neither of Eniola's two strongest tracks (AI-process and neuroinflammatory) is a direct fit for addiction pharmacology or the CCT model as presented. The AI-process track requires a clear process-development angle (media/bioreactor/manufacturing workflow), which IMPRINT/TOPOLOGIX can credibly occupy but only if the proposal explicitly maps the tools to Merck's cell culture or assay manufacturing context — not as standalone drug-discovery tools.
3. No wet-lab capability: The neuroinflammatory track explicitly requires iPSC-derived co-culture models with quantified readouts. Eniola cannot lead that arm alone; she would need a named wet-lab collaborator. Applying solo to that track without a co-PI creates an obvious gap reviewers will flag.
4. Geographic and career-stage optics: Eniola is a 29-year-old independent researcher in Lagos without a PhD. While the programme is nominally open to 'all career stages', the deep-dive workshop is held in Germany in November/December 2026, meaning shortlisting has logistical and visa implications that must be addressed proactively.
5. IP/collaboration terms: Merck requires bilateral collaboration agreements with grantees. ZYCO's provisional patent (Q3 2026) on the CCT architecture could create IP tension — the proposal should explicitly clarify which aspects of the work are pre-existing IP versus new work funded under the grant, and signal willingness to negotiate publication and co-development terms.